Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis

Alain Calender; Dominique Israel-Biet; Dominique Valeyre; Yves Pacheco

doi:10.1016/j.it.2020.08.001

Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis

Trends Immunol. 2020 Oct;41(10):856-859. doi: 10.1016/j.it.2020.08.001. Epub 2020 Aug 10.

Authors

Alain Calender¹, Dominique Israel-Biet², Dominique Valeyre³, Yves Pacheco⁴

Affiliations

¹ Department of Genetics, University Hospital, University Claude Bernard Lyon 1, Lyon, France. Electronic address: alain.calender@chu-lyon.fr.
² Department of Pulmonology AP-HP, Georges Pompidou European Hospital, Paris, France.
³ Department of Pulmonology, Avicenne Hospital, Bobigny, France; Saint Joseph Hospital, APHP, Paris, France; University Sorbonne Paris Nord, INSERM UMR 1272, Villetaneuse, France.
⁴ Department of Genetics, University Hospital, University Claude Bernard Lyon 1, Lyon, France.

Abstract

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mainly affects the lungs. Sarcoidosis is an autoinflammatory disease characterized by the diffusion of granulomas in the lungs and other organs. Here, we discuss how the two diseases might involve some common mechanistic cellular pathways around the regulation of autophagy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Autophagy / drug effects*
Autophagy / genetics
Azithromycin / therapeutic use
Betacoronavirus / growth & development
Betacoronavirus / pathogenicity*
COVID-19
Chloroquine / therapeutic use
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Coronavirus Infections / genetics
Coronavirus Infections / virology
Host-Pathogen Interactions / drug effects
Humans
Isoniazid / therapeutic use
Lung / drug effects
Lung / pathology
Lung / virology
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / genetics
Pneumonia, Viral / virology
Pulmonary Edema / drug therapy*
Pulmonary Edema / epidemiology
Pulmonary Edema / genetics
Pulmonary Edema / virology
Rifampin / therapeutic use
SARS-CoV-2
Sarcoidosis / drug therapy*
Sarcoidosis / epidemiology
Sarcoidosis / genetics
Sarcoidosis / virology
Severe Acute Respiratory Syndrome / drug therapy*
Severe Acute Respiratory Syndrome / epidemiology
Severe Acute Respiratory Syndrome / genetics
Severe Acute Respiratory Syndrome / virology
Severity of Illness Index

Substances

Angiotensin-Converting Enzyme Inhibitors
Azithromycin
Chloroquine
Isoniazid
Rifampin